Abbott product line 200 people were exposed to disbanded!

Medicine network January 18th, there are foreign companies to lay off workers, this time Abbott! Its laid-off workers said: cut 200 jobs, products packaged to a well-known domestic pharmaceutical companiesAbbott cut off the all-annone product line, the team16, a self-proclaimed cut Abbott employee told Saberblue, his Abbott sales team has been dismissedAccording to the employee, who asked not to be named, Abbott had completed the dismissal of the OTC team for the AllAns product line by December 31, 2016The country involved a total of nearly 200 people, productpackaging to the stone pharmaceutical groupon the evening of the 16th, Seiberblue to Abbott Pharmaceuticals China Public Relations Department to verify this information, as of the time of writing, has not yet received a reply from Abbottthe laid-off worker said the team did not get the opportunity to transfer, although not satisfied with only "N1" compensation, but its third partyrecruitmentcompany to be tough, and ultimately can only accept the country's minimum compensation program, take severance pay, leaveAccording to him, the day-to-day management team sent out district managers for Mr Abbott, including the "demobilization order", as well as verbal notices from local regional managersIn fact, Abbott has also made cuts to the district manager of each province of the Quan's product line, leaving only about three peopletwo years self-employed, on the package out, foreign enterprises also began to worry?public information shows that Mr Abbott entered China in August 2014The product is positioned as a nutritionally supplemented all-nutrition formula for postoperative rehabilitation patients and middle-aged and elderly people, providing comprehensive and balanced nutrition and helping to improve nutritional statusIt can also serve as a single source of nutritionProducts are the leading sellers in the U.S., with 100% coming from EuropeAccording to the product promotion for nearly two years of this layoff, the introduction of the entire ansu heyday has fullcoverage of first- and second-tier cities OTC channels, while double cross-yard sales, year-on-year industry, revenue is not bad As for the reason Mr Abbott pulled out of the team and packed it for stone medicine, he said it was "probably not selling well and not meeting the company's expectations." has been, compared with the domestic enterprises impatience, foreign enterprises give people feel to be calm a lot, grass snake line, gray extended thousands of miles In fact, recently, with a certain trend becoming more and more intense, foreign companies have given the impression of a rush Yes, with a series of layoffs and transfers, selling products, although for different reasons, but firmly sitting on a trend - foreign companies are indeed "in a hurry" Roche, Sanofi, GlaxoSmithKline, Squibb and other foreign companies frequently lay off workers, there is a normal trend
according to earlier reports, only at the end of 2016, many multinational pharmaceutical companies in the Chinese market has burst rumors of layoffs Including Roche, Sanofi MeiHuamei, Uber, GlaxoSmithKline, Squibb, Burlinger Ingham and so on According to people familiar with the matter, some of Roche's current colleagues have begun to interview; MeihuaMei is now re-integrated, representatives want to be laid off, waiting for the n-3 compensation, the result has to wait for the initiative to leave; recently, Uefa held a Conference call with the BVT business unit notice, from January 1, 2017, PanfuShu will outsource sales to Shanghai Smykang Biotech Co., Ltd A region began to lay off staff, integration of resources, December 6, 2016, Shi Guibao officially announced the dissolution of the OTC business and its team, there is no transfer, involving a total of about 150 Chinese OTC team
; If you go back from this, there are more cases, not to be listed here these long-standing and experienced foreign companies in the country, or cut staff, or simply cut down the team, find a domestic partner for the product Whether due to market integration considerations, or subject to some pressure of market development, frequent adjustments reflect market volatility on the other hand, based on the increasing lying pressure of medical anti-corruption, coupled with the media, such as CCTV from time to time to intervene exposure pharmaceutical market norms the night before the shock, I am afraid it will continue for some time It is likely that pharmaceutical companies will be more frequent and intensive product adjustment, including foreign enterprises